[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | Sponsor | E-mail ]

Turkish Journal of Cancer
1994, Volume 24, Number 2, Page(s) 78-83
[ Summary ]
ldarubicin in relapsed pediatric acute lymphoblastic leukemia
ALİ PAMİR1, AYHAN O. ÇAVDAR1, SEVGİ GÖZDAŞOĞLU1, EMEL BABACAN1, ULYA ERTEM2, ŞAKİR TANINDI3, GÜLSAN YAVUZ1, EMEL ÜNAL1
1Department of Pediatric Hematology-Oncology, Ankara University Medical School
2Sami Ulus Children’s Hospital
3Gülhane Military Academy, Ankara-Turkey

Idarubicin (IDA) is a new anthracycline derivative which differs from daunorubicin by the replacement of the methoxyl group at position 4 with a proton. A variety of regimens have been used for reinducing patients with acute lymphoblastic leukemia (ALL) in bone marrow relapse. There have been a limited number of IDA studies in childhood leukemia. In this series we administered IDA in 15 relapsed ALL patients. The patients received IDA according to the TUKALL 1 regimen. Twelve patients were evaluable, 8 patients achieved CR (66.6%); duration of remission ranged from 2 to 30 months (mean 11.2±8.3 months). Early death occurred in 25% of the patients due to serious infections and hemorrhages. Grade 3 to 4 myelosuppression was observed in all patients; cardiac toxicity and mucositis were noticed in 16.6% and 58.3% of cases respectively. This preliminary study confirmed the role of IDA in the induction of relapsed ALL in children. Less toxic and more effective IDA containing regimens are needed.

[ Summary ]
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]